Although the precise mechanisms are unknown, an icv injection of a low concentration of STZ induces an AD-like pathology, such as disturbances in brain insulin signaling and glucose utilization, accumulation of Aβ plaques, tau hyperphosphorylation, inflammation, and progressive cognitive impairments, in rodents [26,27,28,29,30]. The gene discussed is MAPT; the disease is Alzheimer disease.